Class 3 MAP2K1 mutations associate with relapse and multiple treatment lines in multisystem Langerhans cell histiocytosis.

Hofer KD, Seydoux C, Angst F, Balabanov S, Bühler MM, Bützberger P, Clarenbach C, Diamond EL, Erlic Z, Honecker F, Hüllner M, Kälin P, Lang C, Song YL, Stiefel R, Manz MG, Rösler W

Open source

DOI: 10.1182/bloodadvances.2025018729
Published: 2026 Sep 8
Container: Blood advances
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/bloodadvances.2025018729,
  title = {Class 3 MAP2K1 mutations associate with relapse and multiple treatment lines in multisystem Langerhans cell histiocytosis.},
  author = {Hofer KD and Seydoux C and Angst F and Balabanov S and Bühler MM and Bützberger P and Clarenbach C and Diamond EL and Erlic Z and Honecker F and Hüllner M and Kälin P and Lang C and Song YL and Stiefel R and Manz MG and Rösler W},
  year = {2026},
  journal = {Blood advances},
  doi = {10.1182/bloodadvances.2025018729},
  url = {https://doi.org/10.1182/bloodadvances.2025018729}
}

RIS

TY  - JOUR
TI  - Class 3 MAP2K1 mutations associate with relapse and multiple treatment lines in multisystem Langerhans cell histiocytosis.
AU  - Hofer KD
AU  - Seydoux C
AU  - Angst F
AU  - Balabanov S
AU  - Bühler MM
AU  - Bützberger P
AU  - Clarenbach C
AU  - Diamond EL
AU  - Erlic Z
AU  - Honecker F
AU  - Hüllner M
AU  - Kälin P
AU  - Lang C
AU  - Song YL
AU  - Stiefel R
AU  - Manz MG
AU  - Rösler W
PY  - 2026
JO  - Blood advances
DO  - 10.1182/bloodadvances.2025018729
UR  - https://doi.org/10.1182/bloodadvances.2025018729
ER  -

APA

KD, H., C, S., F, A., S, B., MM, B., P, B., C, C., EL, D., Z, E., F, H., M, H., P, K., C, L., YL, S., R, S., MG, M., & W, R. (2026). Class 3 MAP2K1 mutations associate with relapse and multiple treatment lines in multisystem Langerhans cell histiocytosis.. Blood advances. https://doi.org/10.1182/bloodadvances.2025018729

Source records

pubmed · retrieved 2026-09-26T19:59:55.741Z